Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2016 Nov;95(46):e5221.
doi: 10.1097/MD.0000000000005221.

Efficacy and safety of addition of bevacizumab to FOLFIRI or irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer: A meta-analysis

Ke Chen  1 , Yinya Gong, Qi Zhang, Yanping Shen, Taoqi Zhou
Affiliations
Meta-Analysis

Efficacy and safety of addition of bevacizumab to FOLFIRI or irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer: A meta-analysis

Ke Chen et al. Medicine (Baltimore). 2016 Nov.

Abstract

Recent studies have paid much attention on the safety of bevacizumab as adjuvant chemotherapy for metastatic colorectal cancer. The aim of this meta-analysis was to study the efficacy and safety of bevacizumab in combination with irinotecan, bolus followed by infusional 5-fluorouracil, and leucovorin (FOLFIRI) and, irinotecan, bolus fluorouracil, leucovorin (IFL) for patients with metastatic colorectal cancer (mCRC).An electronic search of related trials was conducted from PubMed, EMBASE, Cochrane Library databases. Risk ratio (RRs) and its 95% confidence intervals (95% CIs) were calculated by using either DerSimonian-Laird method or Mantel-Haenszel method according to the heterogeneity of included articles. The risk of mortality, therapeutic efficacy, and adverse effect were meta-analyzed.In total, 6 RCTs including 2165 participants (1109 in the treatment group, 1056 in the control group) were included in this meta-analysis. Compared with FOLFIRI-panitumumab/cetuximab, the bevacizumab addition significantly reduced the complete response (CR) rate (RR [95%CI] = 0.31[0.11, 0.89], P = 0.03) and the risk of grade 3/4 adverse event (RR [95%CI] = 0.89[0.80, 0.98], P = 0.01). Compared with FOLFIRI and IFL alone, the addition of bevacizumb significantly increased the partial response (PR) and objective response (OR) rates. Compared with IFL alone, the addition of bevacizumb significantly reduced the mortality risk of PFS (RR [95%CI] = 0.53[0.42, 0.66], P < 0.00001) and OS (RR[95%CI] = 0.70[0.60, 0.82], P < 0.00001), but increased the risk of adverse events (RR[95%CI] = 1.14[1.06, 1.21], P = 0.0002).Combination chemotherapy of bevacizumab plus FOLFIRI or IFL had a relative high efficacy and acceptable safety for treatment of mCRC.

PubMed Disclaimer

Conflict of interest statement

The authors have no funding and conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Literature search and study selection.
Figure 2
Figure 2
Risk bias of included studies.
Figure 3
Figure 3
Forest plot of therapeutic efficiency for the addition of bevacizumab to FOLFIRI or IFL: (A) complete response, (B) partial response, (C) objective response. FOLFIRI = 5-fluorouracil, and leucovorin, IFL = fluorouracil, leucovorin.
Figure 4
Figure 4
Forest plot of mortality risk for the addition of bevacizumab to FOLFIRI or IFL: (A) progression-free survival, (B) overall survival. FOLFIRI = 5-fluorouracil, and leucovorin, IFL = fluorouracil, leucovorin.
Figure 5
Figure 5
Forest plot of adverse effect for the addition of bevacizumab to FOLFIRI or IFL: (A) grade 3/4 side events, (B) treatment discontinued by drug toxicity. FOLFIRI = 5-fluorouracil, and leucovorin, IFL = fluorouracil, leucovorin.
See this image and copyright information in PMC

References

    1. Jemal A, Siegel R, Xu J, et al. Cancer Statistics, 2010. CA Cancer J Clin 2012; 62:10–29. - PubMed
    1. Cutsem EV, Nordlinger B, Adam R, et al. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer 2006; 42:2212–2221. - PubMed
    1. Obrand DI, Gordon PH. Incidence and patterns of recurrence following curative resection for colorectal carcinoma. Dis Colon Rectum 1997; 40:15–24. - PubMed
    1. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362:841–844. - PubMed
    1. Asano M, Yukita A, Matsumoto T, et al. An anti-human VEGF monoclonal antibody, MV833, that exhibits potent anti-tumor activity in vivo. Hybridoma 1998; 17:185–190. - PubMed

Publication types

MeSH terms

Supplementary concepts